Trending...
- Tony Grundler Introduces Artificial Intelligence V.S. Avatar-Ian's
- Cleveland County Goat Farm NC Kikos Featured in "Feature Farmer Friday" Documentary
- The State of Law Firm Marketing: Top Companies, Awards, and Resources
RADNOR, Pa., May 9, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against Natera, Inc. ("Natera") (NASDAQ: NTRA) on behalf of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive (the "Class Period").
CLICK HERE TO SUBMIT YOUR NATERA LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/natera-inc?utm_source=PR&utm_medium=link&utm_campaign=natera&mktm=r
TO VIEW OUR VIDEO, PLEASE CLICK HERE
TO VIEW OUR COMPLAINT, PLEASE CLICK HERE
LEAD PLAINTIFF DEADLINE: JUNE 27, 2022
CLASS PERIOD: FEBRUARY 26, 2020 through APRIL 19, 2022
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. (484) 270-1453 or Email at [email protected]
Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
NATERA'S ALLEGED MISCONDUCT
Natera, a Delaware corporation with principal executive offices in Austin, Texas, offers genetic testing in the areas of women's health, oncology, and organ health. Among other things, the Company produces and markets a non-invasive prenatal test (NIPT), called "Panorama," and a screening test for kidney transplant failure, called "Prospera." Throughout the Class Period, Defendants repeatedly assured investors that Panorama was reliable, that Prospera was more accurate than competing tests, and that Natera's growth was driven by its superior technology and customer experience.
Investors, however, began to learn the truth on January 1, 2022, when The New York Times published a detailed report calling into question the accuracy of certain prenatal tests manufactured by Natera and other diagnostic testing companies. Among other things, The New York Times reported that Natera's positive results for several genetic disorders were incorrect more than 80 percent of the time. On this news, the price of Natera common stock fell $5.35 per share, or approximately 6% over two trading days, from a close of $93.39 per share on December 31, 2021, to close at $88.04 per share on January 4, 2022.
More on The PennZone
Less than two weeks later, on January 14, 2022, the Campaign for Accountability—a nonprofit watchdog group—filed a complaint with the U.S. Securities and Exchange Commission requesting an investigation as to whether Natera repeatedly claimed – in marketing materials and earnings calls – that its tests are much more reliable than it appears they really are. On this news, the price of Natera common stock fell $6.29 per share, or more than 9%, from a close of $67.37 per share on January 14, 2022, to close at $61.08 per share on January 18, 2022.
Then, on March 9, 2022, Hindenburg Research issued an investigative report alleging, among other things, that "Natera's revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers." On this news, the price of Natera common stock fell as much as $28.65 per share, or more than 52%, from a close of $54.75 per share on March 8, 2022, to an intra-day low of $26.10 per share on March 9, 2022.
Several days later, on March 14, 2022, a jury found that Natera had intentionally and willfully misled the public by utilizing false advertisements to market Prospera in violation of federal and state laws. Among other things, the jury found that Natera's marketing falsely claimed that Prospera was more accurate than the competing kidney transplant testing offered by CareDx, Inc. Ultimately, the jury awarded CareDx, Inc. $44.9 million in monetary damages. On this news, Natera common stock fell as much as $8.81 per share, or approximately 22.5%, from an intra-day high of $39.13 per share on March 14, 2022, to close at $30.32 per share on March 15, 2022.
Finally, on April 19, 2022, the United States Food and Drug Administration (FDA) issued a safety communication "to educate patients and health care providers and to help reduce the inappropriate use of [NIPTs]." The FDA cautioned that statements about NIPTs' reliability and accuracy "may not be supported with sound scientific evidence" and revealed the existence of "cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy." The FDA suggested that patients discuss benefits and risks with a healthcare provider before deciding to undergo NIPT or making any pregnancy-related decisions on the basis of NIPT results. In addition, the FDA advised health care providers that they should not rely on NIPT results alone to diagnose chromosomal abnormalities or disorders. Following this news, the price of Natera common stock fell as much as $1.53 per share, or approximately 3.9%, from an intra-day high of $39.63 per share on April 19, 2022, to close at $38.10 per share on April 20, 2022.
The complaint alleges that, throughout the Class Period, the Defendants misrepresented and/or failed to disclose that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants' false and misleading claims about Natera's technology, the company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis.
More on The PennZone
WHAT CAN I DO?
Natera investors may, no later than June 27, 2022, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages Natera investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE
WHO CAN BE A LEAD PLAINTIFF?
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
[email protected]
SOURCE Kessler Topaz Meltzer & Check, LLP
CLICK HERE TO SUBMIT YOUR NATERA LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/natera-inc?utm_source=PR&utm_medium=link&utm_campaign=natera&mktm=r
TO VIEW OUR VIDEO, PLEASE CLICK HERE
TO VIEW OUR COMPLAINT, PLEASE CLICK HERE
LEAD PLAINTIFF DEADLINE: JUNE 27, 2022
CLASS PERIOD: FEBRUARY 26, 2020 through APRIL 19, 2022
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. (484) 270-1453 or Email at [email protected]
Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
NATERA'S ALLEGED MISCONDUCT
Natera, a Delaware corporation with principal executive offices in Austin, Texas, offers genetic testing in the areas of women's health, oncology, and organ health. Among other things, the Company produces and markets a non-invasive prenatal test (NIPT), called "Panorama," and a screening test for kidney transplant failure, called "Prospera." Throughout the Class Period, Defendants repeatedly assured investors that Panorama was reliable, that Prospera was more accurate than competing tests, and that Natera's growth was driven by its superior technology and customer experience.
Investors, however, began to learn the truth on January 1, 2022, when The New York Times published a detailed report calling into question the accuracy of certain prenatal tests manufactured by Natera and other diagnostic testing companies. Among other things, The New York Times reported that Natera's positive results for several genetic disorders were incorrect more than 80 percent of the time. On this news, the price of Natera common stock fell $5.35 per share, or approximately 6% over two trading days, from a close of $93.39 per share on December 31, 2021, to close at $88.04 per share on January 4, 2022.
More on The PennZone
- Over 98% of crypto owners globally don't declare taxes, new report find
- Happreneurs™ Business Community Launches Pittsburgh, PA Chapter with Powerful Network of Founding Leaders
- TicTac Group acquires French EdTech company Distrisoft
- Rhys-Davies, Wright, Norris, Jacinto Highlight Latest Wave of FAN EXPO Philadelphia Celebrity Guests
- Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
Less than two weeks later, on January 14, 2022, the Campaign for Accountability—a nonprofit watchdog group—filed a complaint with the U.S. Securities and Exchange Commission requesting an investigation as to whether Natera repeatedly claimed – in marketing materials and earnings calls – that its tests are much more reliable than it appears they really are. On this news, the price of Natera common stock fell $6.29 per share, or more than 9%, from a close of $67.37 per share on January 14, 2022, to close at $61.08 per share on January 18, 2022.
Then, on March 9, 2022, Hindenburg Research issued an investigative report alleging, among other things, that "Natera's revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers." On this news, the price of Natera common stock fell as much as $28.65 per share, or more than 52%, from a close of $54.75 per share on March 8, 2022, to an intra-day low of $26.10 per share on March 9, 2022.
Several days later, on March 14, 2022, a jury found that Natera had intentionally and willfully misled the public by utilizing false advertisements to market Prospera in violation of federal and state laws. Among other things, the jury found that Natera's marketing falsely claimed that Prospera was more accurate than the competing kidney transplant testing offered by CareDx, Inc. Ultimately, the jury awarded CareDx, Inc. $44.9 million in monetary damages. On this news, Natera common stock fell as much as $8.81 per share, or approximately 22.5%, from an intra-day high of $39.13 per share on March 14, 2022, to close at $30.32 per share on March 15, 2022.
Finally, on April 19, 2022, the United States Food and Drug Administration (FDA) issued a safety communication "to educate patients and health care providers and to help reduce the inappropriate use of [NIPTs]." The FDA cautioned that statements about NIPTs' reliability and accuracy "may not be supported with sound scientific evidence" and revealed the existence of "cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy." The FDA suggested that patients discuss benefits and risks with a healthcare provider before deciding to undergo NIPT or making any pregnancy-related decisions on the basis of NIPT results. In addition, the FDA advised health care providers that they should not rely on NIPT results alone to diagnose chromosomal abnormalities or disorders. Following this news, the price of Natera common stock fell as much as $1.53 per share, or approximately 3.9%, from an intra-day high of $39.63 per share on April 19, 2022, to close at $38.10 per share on April 20, 2022.
The complaint alleges that, throughout the Class Period, the Defendants misrepresented and/or failed to disclose that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants' false and misleading claims about Natera's technology, the company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis.
More on The PennZone
- Genpak Announces Closure of Utah Manufacturing Facility
- Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap
- The AAA Metamorphosis: How Global Gaming Is Redefining Production Standards
- Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
- Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
WHAT CAN I DO?
Natera investors may, no later than June 27, 2022, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages Natera investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE
WHO CAN BE A LEAD PLAINTIFF?
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
[email protected]
SOURCE Kessler Topaz Meltzer & Check, LLP
Filed Under: Business
0 Comments
Latest on The PennZone
- AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
- Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
- National Focus Turns to Global Conflict, Families of Veterans Lost to Suicide Call for Recognition
- New Global Standard for Transparency Across Critical Resources and Energy Markets: SMX (Security Matters) PLC (N A S D A Q: SMX)
- Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
- Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
- ATTAIN Profiles the Invisible Billionaire Who Started With $75 and Died the Richest Man in A
- Kiko Nation Launches Mobile App to Modernize Livestock Management and Digital Animal Registry
- NEW MANAGEMENT BOOK: Creating a Joy-Centric Culture
- QuickTrack by Datalex Transforms Retail Promoter Management with Claude AI and Real-Time Insights
- Kaltra Introduces Seasonal Discounts on Replacement Coils for Carrier, York, and Trane Chillers
- Evolve Construction Mobilizes Commercial Storm Response Across Illinois With AI-Powered Damage Documentation and Public Adjusters Partnership
- New Book Synthesizes Six Peer-Reviewed Research Programs Into Unified Framework for Consciousness
- The World's First Fully Regenerative Economy: Securing Energy, Food, and a Clean Planet
- The State of Law Firm Marketing: Top Companies, Awards, and Resources
- USA Best Book Awards Finalist What Love Leaves Behind Releases March 24
- Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
- Colonial Nissan Helps Drivers Avoid Costly Repairs with Spring Car Maintenance Tips
- ENTOUCH Named Finalist for 2026 North American Inspiring Workplaces Awards
- Cleveland County Goat Farm NC Kikos Featured in "Feature Farmer Friday" Documentary